ENTITY

Jiangsu Hengrui Pharmaceuticals (1276 HK)

316
Analysis
Health Care • China
Jiangsu Hengrui Pharmaceuticals is a global biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative and high-quality drugs. The company focuses on therapeutic areas including oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. It was founded in 1970 and is headquartered in Lianyungang, Jiangsu, China.
more
•12 Jan 2026 08:05

Aequitas: OmniVision Integrated Circuits Group A/H Trading -Weak Retail and Mediocre Insti Demand

OmniVision Integrated Circuits Group (501 HK) (OVIC, 603501 CH), a semiconductor company, raised around US$600m in its H-share listing. In this...

Logo
378 Views
Share
•11 Jan 2026 10:15

A-H Premium Weekly (Jan 9th): Hua Hong Semiconductor, China Coal Energy, Wuxi Apptec, Joinn Lab

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Hua Hong Semiconductor, China Coal Energy, Wuxi Apptec,...

Logo
436 Views
Share
bearish•Lens Technology
•07 Jan 2026 09:48

Lens Technology IPO Lockup - Has Had a Good Run, Cornerstones Could Book Gains

Lens Technology (6613 HK), a precision manufacturing solution provider, raised around US$700m in its H-share listing.  The lockup on its...

Logo
333 Views
Share
•05 Jan 2026 13:10

OmniVision Integrated Circuits Group A/H Listing - Needs More Discount

OmniVision Integrated Circuits Group (603501 CH), a semiconductor company, aims to raise around US$600m in its H-share listing. In this note, we...

Logo
544 Views
Share
•05 Jan 2026 05:17

OmniVision H Share Listing (501 HK): Valuation Insights

OmniVision, a CMOS image sensor (CIS) company, has launched an H Share listing to raise US$617 million. In this note, I discuss the valuation.

Logo
680 Views
Share
x